JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i2.14198ArticleFirsekibart in the Treatment of Acute Gout Attack in a Patient with Chronic Kidney Disease and Progressive Renal Dysfunction: A Case Reporthttps://artdesignp.com/journal/JCNR/10/2/10.26689/jcnr.v10i2.14198HuJing20261022026-03-11Currently, glucocorticoids are the only treatment option for acute gout attacks in patients with chronic kidney disease (CKD) and progressive renal dysfunction. Management becomes particularly challenging when steroid therapy is contraindicated, poorly tolerated, or ineffective. IL-1β monoclonal antibodies offer potent, targeted anti-inflammatory effects and have been approved for the treatment of gout, providing new therapeutic hope for this population. Here, we report a case of a patient with CKD and progressively worsening renal function who experienced an acute gout attack requiring dialysis. Treatment with the IL-1β monoclonal antibody Firsekibart produced rapid and remarkable anti-inflammatory and analgesic effects, effectively controlling the gout attack, improving renal function, and allowing discontinuation of dialysis.

Xie S, Xiao H, Xu L, et al., 2025, A Comprehensive Analysis of Trends in the Burden of Gout in China and Globally From 1990 to 2021. Scientific Reports, 15(1): 3310.

Kannuthurai V, Gaffo A, 2023, Management of Patient with Gout and Kidney Disease: A Review of Available Therapies and Common Missteps. Kidney360, 4(9): e1332–e1340.

Stamp L, Taylor W, Gaffo A, 2021, Variability in Urate-Lowering Therapy Prescribing a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) Physician Survey. Journal of Rheumatology, 48(1): 152–153.

Li C, Sun M, Liu Z, et al., 2025, 2024 Update of Chinese Guidelines for Management of Hyperuricemia and Gout Part II: Recommendations for Patients with Common Comorbidities. International Journal of Rheumatic Diseases, 28(8): e70402.

de Lima J, de Paula A, Yuasa B, et al., 2023, Genetic and Epigenetic Regulation of the Innate Immune Response to Gout. Immunological Investigations, 52(3): 364–397.

Loustau C, Rosine N, Forien M, et al., 2018, Effectiveness and Safety of Anakinra in Gout Patients with Stage 4–5 Chronic Kidney Disease or Kidney Transplantation: A Multicentre, Retrospective Study. Joint Bone Spine, 85(6): 755–760.

Xue Y, Chu T, Hu J, et al., 2025, Firsekibart Versus Compound Betamethasone in Acute Gout Patients Unsuitable for Standard Therapy: A Randomized Phase 3 Trial. Innovation (Cambridge), 6(8): 101015.

Professional Committee for Rheumatism Prevention and Control, 2025, Guideline for Anti-Inflammatory Treatment of Gout, 2025 Edition. Chinese Journal of Rheumatology, 29(11): 897–922.